Lipid oxidative markers are significantly increased in lipoatrophy but not in sustained asymptomatic hyperlactatemia

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue 1, 2003, Pages 45-49

  McComsey, Grace A ^a,b   Morrow, Jason D ^c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Hyperlactatemia; Lipoatrophy; Lipodystrophy; Mitochondrial toxicity; Oxidative markers; Oxidative stress

Indexed keywords

DIDANOSINE; FREE RADICAL; ISOPROSTANE DERIVATIVE; LACTIC ACID; LAMIVUDINE; REACTIVE OXYGEN METABOLITE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ACCURACY; ADULT; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTATE BLOOD LEVEL; LIPID OXIDATION; LIPID PEROXIDATION; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MITOCHONDRION; OXIDATIVE STRESS; PRIORITY JOURNAL;

ACIDOSIS, LACTIC; ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; F2-ISOPROSTANES; FEMALE; HIV INFECTIONS; HUMANS; LIPID PEROXIDATION; LIPODYSTROPHY; MALE; MIDDLE AGED; OXIDATIVE STRESS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0042916024     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200309010-00006     Document Type: Article

References (27)

1. Brinkman K, Smeitink JA, Romijn JA, et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354:1112-1115.
2. Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12:1735-1744.
3. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667.
4. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309-1316.
5. Miller KD, Cameron M, Wood LV, et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med. 2000;133:192-196.
6. Chariot P, Drogou I, De Lacroix-Szmania I, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol. 1999;30:156-160.
7. McComsey G, Paulsen D, Lonergan T, et al. Improvements in mitochondrial DNA levels after substituting ABC or ZDV for d4T in HIV-infected patients with lipodystrophy [poster]. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 2002.
8. Walker UA, Bickel M, Lutke Volksbeck SI, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr. 2002;29:117-121.
9. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion in adipocytes associated with NRTI treatment in HIV-infected individuals [abstract LB/O3]. Presented at the Eighth European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, October 2001.
10. Shikuma CM, Hu N, Milne C, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS. 2001;15:1801-1809.
11. McComsey G, Tan DJ, Lederman M, et al. Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS. 2002;16:513-518.
12. Cherry CL, Gahan ME, McArthur JC, et al. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr. 2002;30:271-277.
13. Lewis W, Copeland WC, Day BJ. Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab Invest. 2001;6:777-790.
14. Yamaguchi T, Katoh I, Kurata S. AZT causes functional and structural destruction of mitochondria, glutathione deficiency and HIV-1 promoter sensitisation. Eur J Biochem. 2002;269:2782-2788.
15. de la Asuncion JG, del Olmo ML, Sastre J, et al. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Invest. 1998;102:4-9.
16. Paulik M, Lancaster M, Croom D, et al. Anti-oxidants rescue NRTI-induced metabolic changes in AKR/J mice. Antiviral Ther. 2000;5(Suppl 5):6-7.
17. Wei YH, Lu CY, Wei CY, et al. Oxidative stress in human ageing and mitochondrial disease-consequences of defective mitochondrial respiration and impaired antioxidant enzyme system. J Physiol (Lond). 2001; 44:1-11.
18. Piccolo G, Banfi P, Azan G, et al. Biological markers of oxidative stress in mitochondrial myopathies with progressive external ophthalmoplegia. J Neurol Sci. 1991;105:57-60.
19. 2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 1990;87:9383-9387.
20. 2-isoprostanes) in carbon tetrachloride hepatotoxicity: an animal model of lipid peroxidation. J Clin Invest. 1992; 90:2502-2507.
21. 2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med. 2000;28:505-513.
22. Morrow JD. The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev. 2000;32:377-385.
23. 2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Meth Enzymol. 1999;300:3-12.
24. McComsey G, Yau L, Southwell H, et al. Elevated lactate levels are uncommon, even in heavily pretreated HIV-infected subjects [poster]. Presented at the Third International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Athens, October 2001.
25. 2-isoprostanes) in smokers-smoking as a cause of oxidative damage. N Engl J Med. 1995;332:1198-1203.
26. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS. 2001;15:795-797.
27. Moyle G. Hyperlactatemia and lactic acidosis: should routine screening be considered? AIDS Reader. 2002;12:344-348.